

Specimen Collected: 19-Jun-23 08:49

CV2.1 IgG Ab CBA with Rflx to Titer, CSF | Received: 19-Jun-23 08:49 Report/Verified: 19-Jun-23 08:51

Procedure	Result	Units	Reference Interval
CV2.1 Ab IgG CBA-IFA Screen, CSF	Detected * t1 i1		[< 1:1]

CV2.1 Ab IgG Titer by CBA-IFA, CSF | Received: 19-Jun-23 08:49 Report/Verified: 19-Jun-23 08:51

Procedure	Result	Units	Reference Interval
CV2.1 Ab IgG CBA-IFA Titer, CSF	1:80 * i2		[<1.1]

Interpretive Text

t1: 19-Jun-23 08:49 (CV2.1 Ab IgG CBA-IFA Screen, CSF)

CV2.1 Antibody, IgG is detected. Titer results to follow. Additional charges apply.

Test Information

i1: CV2.1 Ab IgG CBA-IFA Screen, CSF

INTERPRETIVE INFORMATION: CV2.1 Ab IgG CBA-IFA Screen, CSF

CV2.1 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2.1 is associated with small-cell lung cancer and thymoma. A negative test result does not rule out a diagnosis of autoimmune neurologic disease. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes CV2.1 transfected cell lines for the detection and semiquantification of the CV2.1 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i2: CV2.1 Ab IgG CBA-IFA Titer, CSF

INTERPRETIVE INFORMATION: CV2.1 Ab IgG CBA-IFA Titer, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:**ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-170-900040**Report Request ID:** 17763815**Printed:** 19-Jun-23 11:56

Page 1 of 1